Item 16. FORM 10-K SUMMARY
19K characters. Original on sec.gov · Markdown
Item 16. FORM 10-K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)
By: /s/ Bernard J. Birkett
Bernard J. Birkett
Senior Vice President and Chief Financial Officer
February 21, 2020
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of West Pharmaceutical Services, Inc. in the capacities and on the dates indicated.
| Signature | Title | Date | ||||||
| /s/ Eric M. Green | Director, President and Chief Executive Officer | February 21, 2020 | ||||||
| Eric M. Green | (Principal Executive Officer) | |||||||
| /s/ Bernard J. Birkett | Senior Vice President and Chief Financial Officer | February 21, 2020 | ||||||
| Bernard J. Birkett | (Principal Financial Officer and Principal Accounting Officer) | |||||||
| /s/ Mark A. Buthman | Director | February 18, 2020 | ||||||
| Mark A. Buthman | ||||||||
| /s/ William F. Feehery, Ph.D. | Director | February 18, 2020 | ||||||
| William F. Feehery, Ph.D. | ||||||||
| /s/ Robert F. Friel | Director | February 18, 2020 | ||||||
| Robert F. Friel | ||||||||
| /s/ Thomas W. Hofmann | Director | February 18, 2020 | ||||||
| Thomas W. Hofmann | ||||||||
| /s/ Paula A. Johnson, M.D., MPH | Director | February 18, 2020 | ||||||
| Paula A. Johnson, M.D., MPH | ||||||||
| /s/ Deborah L.V. Keller | Director | February 18, 2020 | ||||||
| Deborah L.V. Keller | ||||||||
| /s/ Myla P. Lai-Goldman, M.D. | Director | February 18, 2020 | ||||||
| Myla P. Lai-Goldman, M.D. | ||||||||
| /s/ Douglas A. Michels | Director | February 18, 2020 | ||||||
| Douglas A. Michels | ||||||||
| /s/ Paolo Pucci | Director | February 18, 2020 | ||||||
| Paolo Pucci | ||||||||
| /s/ Patrick J. Zenner | Director and Chairman of the Board | February 18, 2020 | ||||||
| Patrick J. Zenner |
EXHIBIT INDEX
F-1
F-2
| Exhibit Number | Description | ||||
| 32.1* | Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2* | Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101.INS | The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
| 104** | Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set. |
(1) We agree to furnish to the SEC, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.
(2) Management compensatory plan.
(3) Certain portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment order of the SEC.
(4) Portions of this exhibit (indicated therein by asterisks) have been omitted for confidential treatment.
- Furnished, not filed.
F-3
Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES